Public disclosures

AIM insider disclosures

Explore public SEC filings by reporting investor and stock. Filings can appear after the activity they describe. Joint filing lines link to each reporting owner’s profile.

Advertisement
More filters
Clear filters
Reporting investorSecurityActivityTransaction / periodFiledReported amountSourceFollow
KELLNER TED D

Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Other transaction
Filing details

SEC transaction code D

Common Stock · Indirect ownership · By Kellner,Ted Combined Profit Sharing/Money Purchase Plan · Reported balance after transaction: 0 · Shares held by the Kellner, Ted Combined Profit Sharing/Money Purchase Plan, for which the reporting person serves as trustee.

2026-11-182026-11-20

250 shares/units

SEC 4Follow
KELLNER TED D

Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Other transaction
Filing details

SEC transaction code D

Common Stock · Indirect ownership · By Beta Fund Investment Club · Reported balance after transaction: 0 · Shares held by the Beta Fund Investment Club, for which the reporting person serves as the manager and is an investor. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

2026-11-182026-11-20

2,702 shares/units

SEC 4Follow
KELLNER TED D

Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Other transaction
Filing details

SEC transaction code D

Common Stock · Indirect ownership · By Kelvest ILP · Reported balance after transaction: 19714 · Shares held by Kelvest I LP, for which the reporting person serves as Manager of T&M Partners LLC, General Partner of Kelvest I LP.

2026-11-182026-11-20

14,574 shares/units

SEC 4Follow
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 436095 · SEC code covers open-market or private transactions

2026-11-192026-11-20

≈ $6,550.00

50,000 shares/units

SEC 4Follow
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 386095 · SEC code covers open-market or private transactions

2026-11-182026-11-18

≈ $2,680.00

20,000 shares/units

SEC 4Follow
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 366095 · SEC code covers open-market or private transactions

2026-11-162026-11-17

≈ $5,130.00

38,000 shares/units

SEC 4Follow
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 328095 · SEC code covers open-market or private transactions

2026-11-112026-11-13

≈ $5,215.00

35,000 shares/units

SEC 4Follow
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 293095 · SEC code covers open-market or private transactions

2026-11-102026-11-12

≈ $5,382.00

39,000 shares/units

SEC 4Follow
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 254095 · SEC code covers open-market or private transactions

2026-11-092026-11-10

≈ $5,070.28

31,298 shares/units

SEC 4Follow
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 222797 · SEC code covers open-market or private transactions

2026-11-062026-11-09

≈ $2,014.66

12,751 shares/units

SEC 4Follow
Equels Thomas K

CEO & President · Director · AIM ImmunoTech Inc.

AIM

AIM ImmunoTech Inc.

Buy
Filing details

SEC transaction code P

Common Stock · Direct ownership · Reported balance after transaction: 210046 · SEC code covers open-market or private transactions

2026-11-062026-11-06

≈ $3,166.64

20,299 shares/units

SEC 4Follow

Form 4 buy and sell codes cover open-market or private transactions. Form 13F shows quarterly reported holdings. Position changes can have causes other than trading. Disclosures are delayed and provided for research.

Advertisement